Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been given an average recommendation of “Moderate Buy” by the eight research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $6.60.

CNTX has been the subject of several recent research reports. D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Tuesday, March 24th. Piper Sandler boosted their target price on shares of Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. Wall Street Zen lowered shares of Context Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 29th. Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. Finally, Guggenheim reiterated a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research note on Tuesday, March 24th.

Context Therapeutics Price Performance

CNTX stock opened at $2.51 on Wednesday. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.62. The firm has a fifty day moving average price of $2.62 and a two-hundred day moving average price of $1.87. The firm has a market cap of $230.62 million, a price-to-earnings ratio of -6.61 and a beta of 1.82.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Monday, March 23rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). As a group, analysts expect that Context Therapeutics will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Several institutional investors have recently modified their holdings of CNTX. Clear Harbor Asset Management LLC grew its position in shares of Context Therapeutics by 60.5% during the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after acquiring an additional 35,000 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after acquiring an additional 134,449 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Context Therapeutics during the third quarter worth about $100,000. Blue Owl Capital Holdings LP grew its position in shares of Context Therapeutics by 0.3% during the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock worth $10,926,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after acquiring an additional 188,202 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.